JP2020523029A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523029A5
JP2020523029A5 JP2019569397A JP2019569397A JP2020523029A5 JP 2020523029 A5 JP2020523029 A5 JP 2020523029A5 JP 2019569397 A JP2019569397 A JP 2019569397A JP 2019569397 A JP2019569397 A JP 2019569397A JP 2020523029 A5 JP2020523029 A5 JP 2020523029A5
Authority
JP
Japan
Prior art keywords
seq
antibody
cancer
hue71
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019569397A
Other languages
English (en)
Japanese (ja)
Other versions
JP7353187B2 (ja
JP2020523029A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037645 external-priority patent/WO2018232188A1/en
Publication of JP2020523029A publication Critical patent/JP2020523029A/ja
Publication of JP2020523029A5 publication Critical patent/JP2020523029A5/ja
Application granted granted Critical
Publication of JP7353187B2 publication Critical patent/JP7353187B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019569397A 2017-06-15 2018-06-14 抗l1-cam抗体およびその使用 Active JP7353187B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762520382P 2017-06-15 2017-06-15
US62/520,382 2017-06-15
PCT/US2018/037645 WO2018232188A1 (en) 2017-06-15 2018-06-14 Anti-l1-cam antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2020523029A JP2020523029A (ja) 2020-08-06
JP2020523029A5 true JP2020523029A5 (https=) 2021-07-26
JP7353187B2 JP7353187B2 (ja) 2023-10-05

Family

ID=64660699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569397A Active JP7353187B2 (ja) 2017-06-15 2018-06-14 抗l1-cam抗体およびその使用

Country Status (7)

Country Link
US (2) US11597764B2 (https=)
EP (1) EP3638299A4 (https=)
JP (1) JP7353187B2 (https=)
CN (2) CN111093693B (https=)
CA (1) CA3067351A1 (https=)
IL (1) IL271398A (https=)
WO (1) WO2018232188A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd8에의 항원 결합 구조체들
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
US11597764B2 (en) * 2017-06-15 2023-03-07 Memorial Sloan Kettering Cancer Center Anti-L1-CAM antibodies and uses thereof
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
EP3938400B1 (en) 2019-03-11 2025-07-30 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
CA3136251A1 (en) * 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
JP2023525581A (ja) * 2020-05-15 2023-06-16 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体の活性化を検出するための細胞外小胞の使用方法、並びに補体性疾患の処置を評価及び/又は監視するためのその使用
CN114558122B (zh) * 2022-04-27 2023-02-21 北京肿瘤医院(北京大学肿瘤医院) 放射核素标记的过氧化氢酶及其应用
CA3262904A1 (en) * 2022-09-21 2024-03-28 Elthera Ag NEW BINDING MOLECULES THAT BIND TO L1CAM
EP4615580A1 (en) 2022-11-09 2025-09-17 CIS Biopharma AG Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
WO2025238187A1 (en) 2024-05-15 2025-11-20 Cis Biopharma Ag Immunoconjugates targeting l1-cam

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US6972323B1 (en) * 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
WO2007114550A1 (en) * 2006-04-03 2007-10-11 Korea Research Institute Of Bioscience And Biotechnology A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
AU2007254853B2 (en) * 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
CA2661669C (en) * 2006-08-23 2017-02-14 Korea Research Institute Of Bioscience And Biotechnology A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangniocarcinoma
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
KR101501736B1 (ko) 2008-12-05 2015-03-12 한국생명공학연구원 인간 및 마우스에서 발현하는 l1cam에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
AU2011333738A1 (en) * 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
ES2692268T5 (en) * 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EP2793947B1 (en) 2011-12-23 2021-02-03 Innate Pharma Enzymatic conjugation of polypeptides
WO2014077648A1 (ko) 2012-11-16 2014-05-22 강원대학교산학협력단 인간 및 마우스 l1cam 단백질에 특이적으로 결합하는 항체 및 이의 용도
WO2015051199A2 (en) * 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
US11597764B2 (en) * 2017-06-15 2023-03-07 Memorial Sloan Kettering Cancer Center Anti-L1-CAM antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2020523029A5 (https=)
Wei et al. Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Goebeler et al. Bispecific and multispecific antibodies in oncology: opportunities and challenges
Paul et al. Cancer therapy with antibodies
Barzaman et al. Breast cancer immunotherapy: Current and novel approaches
JP2022546572A5 (https=)
IL273484B1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
JP2021531764A5 (https=)
JP2023523584A5 (https=)
JP2020534017A5 (https=)
JP2020103301A5 (https=)
Chandramohan et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy
Lutterbuese et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA
JP2020534250A5 (https=)
JP2022538117A5 (https=)
JP2023537002A5 (https=)
JP2020501531A5 (https=)
JP2021517816A5 (https=)
JP2021520208A5 (https=)
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2020507571A5 (https=)
JP2020512281A5 (https=)
JP2015529641A5 (https=)
US20240197931A1 (en) Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells
JP2024530166A5 (https=)